CSIR-NIIST - Golden Jubilee Curtain Raiser

On July 26, 2024, Olusium Technologies signed second Memorandum of Understanding (MoU) with CSIR-NIIST to initiate a multicentric phase of validation for their pioneering early-stage cancer detection technology across various geographical regions in India. The MoU was exchanged in the esteemed presence of Dr. (Mrs.) N. Kalaiselvi, Director General of CSIR and Secretary of DSIR, marking a significant milestone in the collaboration between Olusium and CSIR-NIIST. This partnership aims to rigorously test and validate the technology's efficacy in diverse clinical settings, paving the way for its widespread adoption in the early diagnosis of cancer.

CSIR-NIIST, TATA ELXSI, OLUSIUM, CANCER INSTITUTE (WIA), at Golden Jubilee Curtain Raiser Program

On July 26, 2024, Olusium Technologies officially exchanged a Memorandum of Understanding (MoU) with the Council of Scientific and Industrial Research - National Institute for Interdisciplinary Science and Technology (CSIR-NIIST) to advance the validation of its early-stage cancer detection technology. This collaboration will involve multicentric validation phases across India, conducted in partnership with the Tata Elxsi and Cancer Institute (WIA). The MoU exchange took place in the esteemed presence of Dr. (Mrs.) N. Kalaiselvi, Director General of CSIR and Secretary of the Department of Scientific and Industrial Research (DSIR), marking a significant milestone in the pursuit of cutting-edge, non-invasive diagnostic solutions for cancer.

One Week One Lab (OWOL) program at CSIR-NIIST - 28th February 2023

The "One Week One Lab (OWOL) program" conducted at CSIR-NIIST on February 28, 2023, showcased remarkable strides in cutting-edge research. In a groundbreaking presentation, Olusium Technologies in Advanced Research unveiled their pioneering advancements in the realm of early-stage cancer diagnosis technologies. The event marked a significant step forward in the fight against cancer, with Olusium's technical demonstration shedding light on innovative methodologies designed to identify and diagnose cancer at its nascent stages. This convergence of expertise between Olusium and CSIR-NIIST underscores the potential to revolutionize healthcare by harnessing the power of technology and research to detect and combat cancer more effectively, ultimately offering new hope to patients and medical professionals alike.

TIFAC-DSIR-NIIST joint workshop on TRL6 and above technology assessment held at CSIR-NIIST,Olusium

The TIFAC-DSIR-NIIST joint workshop on Technology Readiness Levels (TRL) 6 and above assessment, hosted at CSIR-NIIST, marked a significant gathering of experts and innovators. A highlight of the event was Olusium Technologies in Advanced Research sharing their pioneering endeavors in the field of healthcare. Focusing on early-stage cancer diagnosis, the company unveiled its state-of-the-art novel technology, seamlessly integrated with advanced Embedded-Artificial Intelligence capabilities. During the workshop, Olusium candidly expressed the challenges they encountered in executing this groundbreaking concept. The convergence of cutting-edge technology and healthcare is poised to revolutionize medical diagnosis, with Olusium at the forefront of this innovative intersection. The workshop provided a platform for cross-disciplinary dialogue and collaborative problem-solving, further propelling the advancements in TRL 6 and beyond technologies.

Technical Talk on Non-Invasive Disease Diagnosis

This talk at the prestigious Engineering Institution in the world had a warm welcome. The talk was about the non-invasive disease diagnosis and its feature along with health informatics.

Non-Invasive Early Stage Breast Cancer Diagnosis.

This state-of-the-art indigenous screening method that is designed to diagnose cancer initally and other anomalies as well noninvasively and without any pain. One of the key advantages of this screening technique is that it emits no radiation, making it an ideal alternative to traditional screening methods that involve exposure to ionizing radiation. This real-time rapid identification technique uses advanced propiretary technologies and multi-tier artificial intelligence algorithms to quickly and accurately analyze and identify potential cancers.

• Real-Time.
• Label Free.
• Results in less than 3 minutes.
• No pain and no preparations needed.
• Cost-Effective.